Volume 9 Issue 4
Jul.  2018
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-7445.2018.04.015
  • Received Date: 2018-05-16
    Available Online: 2021-01-19
  • Publish Date: 2018-07-15
  • loading
  • [1]
    MESSINA M, GALLO E, MELLA A, et al. Update on the treatment of focal segmental glomerulosclerosis in renal transplantation[J]. World J Transplant, 2016, 6(1): 54-68. DOI: 10.5500/wjt.v6.i1.54.
    [2]
    D' AGATI VD, KASKEL FJ, FALK RJ. Focal segmental glomerulosclerosis[J]. N Engl J Med, 2011, 365(25): 2398-2411. DOI: 10.1056/NEJMra1106556.
    [3]
    PONTICELLI C, GLASSOCK RJ. Posttransplant recurrence of primary glomerulonephritis[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2363-2372. DOI: 10.2215/CJN.06720810.
    [4]
    VINAI M, WABER P, SEIKALY MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review[J]. Pediatr Transplant, 2010, 14(3): 314-325. DOI: 10.1111/j.1399-3046.2009.01261.x.
    [5]
    JUNGRAITHMAYR TC, HOFER K, COCHAT P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation[J]. J Am Soc Nephrol, 2011, 22(3): 579-585. DOI: 10.1681/ASN.2010010029.
    [6]
    SHARMA M, SHARMA R, MCCARTHY ET, et al. " The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma[J]. J Am Soc Nephrol, 1999, 10(3):552-561.
    [7]
    LE BERRE L, GODFRIN Y, GÜNTHER E, et al. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats[J]. J Clin Invest, 2002, 109(4): 491-498. doi: 10.1172/JCI0212858
    [8]
    GALLON L, LEVENTHAL J, SKARO A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation[J]. N Engl J Med, 2012, 366(17): 1648-1649. DOI: 10.1056/NEJMc1202500.
    [9]
    WEI C, EL HINDI S, LI J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis[J]. Nat Med, 2011, 17(8): 952-960. DOI: 10.1038/nm.2411.
    [10]
    ALACHKAR N, WEI C, AREND LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy[J]. Transplantation, 2013, 96(7): 649-656. DOI: 10.1097/TP.0b013e31829eda4f.
    [11]
    SINHA A, BAJPAI J, SAINI S, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children[J]. Kidney Int, 2014, 85(3): 649-658. DOI: 10.1038/ki.2013.546.
    [12]
    WADA T, NANGAKU M, MARUYAMA S, et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease[J]. Kidney Int, 2014, 85(3): 641-648. DOI: 10.1038/ki.2013.544.
    [13]
    MEIJERS B, MAAS RJ, SPRANGERS B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis[J]. Kidney Int, 2014, 85(3): 636-640. DOI: 10.1038/ki.2013.505.
    [14]
    DOYLE SL, OZAKI E, BRENNAN K, et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration[J]. Sci Transl Med, 2014, 6(230): 230ra44. DOI: 10.1126/scitranslmed.3007616.
    [15]
    REISER J, VON GERSDORFF G, LOOS M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome[J]. J Clin Invest, 2004, 113(10): 1390-1397. doi: 10.1172/JCI20402
    [16]
    YU CC, FORNONI A, WEINS A, et al. Abatacept in B7-1-positive proteinuric kidney disease[J]. N Engl J Med, 2013, 369(25): 2416-2423. DOI: 10.1056/NEJMoa1304572.
    [17]
    GEBESHUBER CA, KORNAUTH C, DONG L, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1[J]. Nat Med, 2013, 19(4): 481-487. DOI: 10.1038/nm.3142.
    [18]
    PONTICELLI C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation[J]. Nephrol Dial Transplant, 2010, 25(1): 25-31. DOI: 10.1093/ndt/gfp538.
    [19]
    GOHH RY, YANGO AF, MORRISSEY PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients[J]. Am J Transplant, 2005, 5(12): 2907-2012. doi: 10.1111/j.1600-6143.2005.01112.x
    [20]
    SALOMON R, GAGNADOUX MF, NIAUDET P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children[J]. Transplantation, 2003, 75(6): 810-814. doi: 10.1097/01.TP.0000055215.20367.21
    [21]
    FORNONI A, SAGESHIMA J, WEI C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis[J]. Sci Transl Med, 2011, 3(85): 85ra46. DOI: 10.1126/scitranslmed.3002231.
    [22]
    AUDARD V, KAMAR N, SAHALI D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation[J]. Transpl Int, 2012, 25(5):e62-e66. DOI: 10.1111/j.1432-2277.2012.01462.x.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (145) PDF downloads(12) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return